CICOT.HL
Finland Researchers study how it targets visceral fat, a key factor in obesity and metabolic disorders
They operate through completely different biological mechanisms, and GLP-1 drugs typically produce much stronger weight loss results
Tirzepatide is structurally based on the native GIP peptide sequence with modifications that confer dual GIP and GLP-1 receptor agonism from a single molecule, along with a fatty acid conjugation that extends the half-life to approximately five days and promotes albumin binding for sustained blood levels between weekly injections
We combine physician-guided medical therapy with metabolic testing, body composition analysis, required laboratory evaluation, nutrition support and functional medicine strategies to help patients lose weight in a healthier, more sustainable way
ETD between tirzepatide and placebo in study 2 was 17.3% (95% CI 19.3 to 15.3) for body weight, 23.8 events per hour (95% CI 29.6 to 17.9) for AHI and 61.3%min h 1 (95% CI 84.7 to 37.9) for SASHB 13
